CLINICAL_TRIALS
trial_result
· 2016-10-21
Clinical Trial Update: A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis [Phase 3]
Summary
Phase 3 study assessing early activity of ixekizumab in moderate-to-severe psoriasis completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2016-10-21